Metabolism of [123I]epidepride may affect brain dopamine D2 receptor imaging with single-photon emission tomography

Kim A. Bergström, Meixiang Yu, Jyrki T. Kuikka, Kari K. Åkerman, Jukka Hiltunen, Johannes Lehtonen, Christer Halldin, Jari Tiihonen

Research output: Contribution to journalArticle

5 Scopus citations

Abstract

Iodine-123 labelled epidepride is a novel radiopharmaceutical for the study of cerebral dopamine D2 receptors using single-photon emission tomography (SPET). A lipophilic labelled metabolite of [123I]epidepride which may enter the brain and hamper the quantitation of receptors has been observed in human plasma. In the present study, gradient high-performance liquid chromatography (HPLC) was used to investigate the plasma concentration of the lipophilic labelled metabolite and its correlation to SPET imaging of striatal dopamine D2 receptors. A linear regression fit showed a negative correlation between the amount of the lipophilic labelled metabolite and the striatum to cerebellum ratio (n=16, R=-0.58, P<0.02), suggesting that plasma metabolite analysis is essential when imaging dopamine D2 receptors with SPET using [123I]epidepride.

Original languageEnglish (US)
Pages (from-to)206-208
Number of pages3
JournalEuropean Journal of Nuclear Medicine
Volume27
Issue number2
DOIs
StatePublished - 2000

Keywords

  • Epidepride
  • High- performance liquid chromatography
  • Metabolites
  • Single-photon emission tomography

ASJC Scopus subject areas

  • Radiology Nuclear Medicine and imaging

Fingerprint Dive into the research topics of 'Metabolism of [<sup>123</sup>I]epidepride may affect brain dopamine D<sub>2</sub> receptor imaging with single-photon emission tomography'. Together they form a unique fingerprint.

Cite this